<DOC>
	<DOCNO>NCT00555373</DOCNO>
	<brief_summary>Damage scar transplanted kidney become common cause loss transplant kidney . This kidney damage complex process cause many factor include injury obtain transplant kidney , injury immune system , injury infection , injury drug use stop rejection . This injury lead scar decrease kidney 's ability function properly , time kidney lose . Prograf速 ( tacrolimus ) one main drug use prevent rejection . However , use time show cause chronic damage scar transplanted kidney . The purpose experimental study determine whether child safely withdraw Prograf速 transplantation change Rapamycin速 ( sirolimus ) . Recent research study adult transplantation demonstrate use Rapamycin速 ( sirolimus ) , possible discontinue use Prograf ( tacrolimus ) increase rejection , decrease scar kidney , improvement kidney function survival kidney . A total 50 child enroll study university center around country . This study last 3 year .</brief_summary>
	<brief_title>Pediatric Kidney Transplant Study Sirolimus , Mycophenolate Mofetil , Corticosteroids v Calcineurin Inhibitor Based Immunosuppression</brief_title>
	<detailed_description>Advances immunosuppressive therapy pediatrics associate rapidly fall incidence acute rejection improve allograft survival . In recent analysis NAPRTCS database , acute rejection longer common cause hospitalization allograft failure . Chronic rejection become common cause allograft failure account 35 % allograft loss . Chronic rejection complex clinical condition include immunologic non-immunologic cause accurately refer Chronic Allograft Nephropathy ( CAN ) . Although Calcineurin inhibitor ( CNI ) play central role reduce acute rejection improve allograft survival , long show contribute interstitial fibrosis chronic allograft nephropathy . Recent trial adult transplantation demonstrate use TOR-inhibitor , Sirolimus , possible withdraw Calcineurin inhibitor increase rejection improvement allograft function , interstitial fibrosis long term survival ( 1 ) . We hypothesize use Sirolimus ( SRL ) pediatric kidney transplantation allow withdrawal Calcineurin inhibitor improve kidney function long term survival . We plan enroll 50 patient time transplantation . Patients receive routine immunosuppression CNI ( Prograf ) , Mycophenolate mofetil ( Cellcept ) prednisone . Those patient normal function rejection episodes 6 month transplantation undergo slow conversion Prograf Sirolimus ( Rapamune ) . We assess rate rejection , allograft function , fibrosis biopsy , allograft survival follow 18 month .</detailed_description>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion Criteria Transplant : Age &lt; 19 year ( day 19th birthday ) Panel Reactive Antibody Level ( PRA ) &lt; 20 % ( Flow cytometry method ) Recipient first live donor decease donor renal transplantation Signed date informed consent ( per local IRB standard ) Exclusion Criteria Transplant : Recipients multiorgan transplant ( e.g . kidney/pancreas transplant , etc . ) Peak PRA &gt; 20 % time Recipient enbloc kidney Recipient organ HLA identical donor nonheart beat donor Pregnant lactate Positive HIV immunodeficiency virus History malignancy Use investigational agent within 4 week prior transplantation Current use terfenadine , cisapride , astemizole , pimozide ( unless discontinue administration SRL ) Known hypersensitivity sirolimus Known hypersensitivity Prograf , Cellcept , prednisone , Cremophor , HCO60 , murine product</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Renal</keyword>
	<keyword>Transplant</keyword>
</DOC>